Mometasona Furoato Teva (Mometasone Furoate)

Mometasone furoate acts as a potent glucocorticoid receptor agonist. After binding to the receptor inside nasal epithelial cells, it modulates gene expression to suppress the production of inflammatory cytokines, chemokines and other mediators, thereby reducing swelling and irritation of the nasal mucosa.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s age, severity of symptoms and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but the exact regimen should always follow the healthcare professional’s instructions.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency corticosteroid with a low systemic bioavailability, offering effective symptom control at low daily doses. Compared with agents such as fluticasone propionate, it provides similar anti‑inflammatory efficacy but may have a slightly longer residence time in the nasal mucosa, allowing once‑daily dosing for many patients.

Store the nasal spray at room temperature, away from direct sunlight and moisture. Keep the device in its original packaging until use, and ensure the cap is tightly closed after each administration to maintain product stability.

Prime the spray by pressing the actuator several times until a fine mist appears. Gently blow the nose, tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril with a finger, and spray the prescribed number of sprays while breathing in gently. Repeat in the other nostril if directed.

Serious adverse events, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal passages. Patients should seek immediate medical attention if they notice persistent nosebleeds, vision changes, or signs of systemic corticosteroid effects.

The spray should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal mucosa, and in children younger than the age specified by the local regulatory authority.